Dirk Sibbing on The Importance of ISAR-REACT 5 trial and 2020 ESC Guidelines for ACS
Dirk Sibbing, Professor, Cardiologist and Angiologist at Lauterbacher Mill Private Clinic and LMU Munich, shared on LinkedIn:
”Very impressive and important data published in EuroIntervention today, showing how impactful data from randomized trials can be…
In 2019, the randomized ISAR-REACT 5 trial demonstrated superiority of prasugrel over ticagrelor for treatment of ACS patients undergoing PCI
In consequence, the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation included a new COR IIa in preference for prasugrel for ACS-PCI
Then, an entire (!) country (Denmark) shifted treatment from routine use of ticagrelor over to prasugrel.
Results of this „real-life“ experiment are now published in Eurointervention
In 10,984 patients, prasugrel was associated with reduced 1-year rate of MACE (adjHR 0.67) and MI (adjHR 0.65), without differences in bleeding risk.
Risk reductions from randomized (ISAR-REACT 5) vs. observational data (Denmark) were very similar, thereby supporting current guideline recommendations
A great example for how impactful clinical trial data can be for the benefit of our patients.”
Read the full article here.
Article: Impact of shifting from routine use of ticagrelor to prasugrel in myocardial infarction patients after PCI: a nationwide cohort study
Authors: Mia Ravn Jacobsen, Peter Laursen Graversen, Reza Jabbari, Erik Lerkevang Grove, Charlotte Glinge, Lene Holmvang, Tobias Geisler, Lars Køber, Christian Torp-Pedersen, Thomas Engstrøm, Rikke Sørensen
Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Feb 22, 2026, 14:16Ilenia Calcaterra: From Representation to Intellectual Independence in Women in Science
-
Feb 22, 2026, 13:27Pete Stibbs: New AHA and ACC PE Guidelines Finally Align with Real Clinical Practice
-
Feb 22, 2026, 10:39Tagreed Alkaltham: Fibrinogen Concentrate Is a Deliberate Clinical Choice in Acute Bleeding
-
Feb 22, 2026, 09:38Abdulrahman Nasiri: Significant Shifts In The 2026 AHA/ACC Guidelines for Acute Pulmonary Embolism
-
Feb 22, 2026, 09:22Shiny K. Kajal: Not All Transfusion Reactions Are Immunohematologic Incompatibilities
-
Feb 22, 2026, 09:12Arun V J։ The Hidden Risks in Every Blood Bag
-
Feb 22, 2026, 08:56Parandzem Khachatryan։ How Hard Is It to Be a Mom, a Wife, a Professor, and a Doctor All at Once?
-
Feb 22, 2026, 08:46Anirban Sen Gupta Presents Bioinspired Platelet Surrogates at MTEC
-
Feb 22, 2026, 08:31Heghine Khachatryan: Advancing Care for Women and Girls with Bleeding Disorders is A Matter of Equity